Scholarlink

<p>We evaluated the feasibility and clinical outcomes of MRIgSBRT for nodal recurrence in the oligometastatic disease (OMD) setting, focusing on per-lesion outcomes and prognostic factors. We collected clinical and dosimetric data from a retrospective single-center cohort of patients treated with a 0.35&#xa0;T MRIgSBRT for nodal recurrences. Endpoints included the 1-year progression-free survival (PFS), local progression-free survival (LPFS), and 3-year overall survival (OS) rate from recurrence. Per-lesion Kaplan–Meier and Cox regression assessed clinical, dosimetric, and technical predictors. 71 patients received nodal MRIgSBRT, with a total of 115 treated metastatic lesions. Local control was high: LPFS 95.5% at 12&#xa0;months and 94.0% at 24/36&#xa0;months. OS was favorable (100% at 12&#xa0;months, 97.2% at 24&#xa0;months, 95.3% at 36&#xa0;months). Systemic progression drove most events: PFS 52.6% at 12&#xa0;months and 24.4% at 24&#xa0;months; median 12.4&#xa0;months. No clinically relevant acute or late toxicity was observed. On multivariable analysis, BED<sub>10</sub> ≥ 70&#xa0;Gy was independently associated with improved OS. Multiple metastases increased the risk of local failure in univariate analysis (UVA) (HR 6.30, <i>p</i> = 0.027). MRIgSBRT represents a safe and viable treatment option in nodal oligometastatic setting. It provides excellent and durable local control with minimal toxicity. As distant progression remains the main challenge, careful selection in low-burden disease, dose escalation to BED<sub>10</sub> ≥ 70&#xa0;Gy, and thoughtful integration with systemic therapy emerge as key levers to optimize outcomes. Further prospective studies are needed to assess OMD long-term survival and quality of life and to evaluate possible further treatment optimization strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Magnetic resonance-guided stereotactic body radiotherapy (MRIgSBRT) for nodal disease in oligometastatic setting: a single-institution study

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Giuditta Chiloiro,
  • Giulia Panza,
  • Angela Romano,
  • Rosa Autorino,
  • Ciro Mazzarella,
  • Gabriele Turco,
  • Marco Valerio Antonelli,
  • Matteo Nardini,
  • Simone Raggio,
  • Lorenzo Placidi,
  • Maria Antonietta Gambacorta,
  • Luca Boldrini

摘要

We evaluated the feasibility and clinical outcomes of MRIgSBRT for nodal recurrence in the oligometastatic disease (OMD) setting, focusing on per-lesion outcomes and prognostic factors. We collected clinical and dosimetric data from a retrospective single-center cohort of patients treated with a 0.35 T MRIgSBRT for nodal recurrences. Endpoints included the 1-year progression-free survival (PFS), local progression-free survival (LPFS), and 3-year overall survival (OS) rate from recurrence. Per-lesion Kaplan–Meier and Cox regression assessed clinical, dosimetric, and technical predictors. 71 patients received nodal MRIgSBRT, with a total of 115 treated metastatic lesions. Local control was high: LPFS 95.5% at 12 months and 94.0% at 24/36 months. OS was favorable (100% at 12 months, 97.2% at 24 months, 95.3% at 36 months). Systemic progression drove most events: PFS 52.6% at 12 months and 24.4% at 24 months; median 12.4 months. No clinically relevant acute or late toxicity was observed. On multivariable analysis, BED10 ≥ 70 Gy was independently associated with improved OS. Multiple metastases increased the risk of local failure in univariate analysis (UVA) (HR 6.30, p = 0.027). MRIgSBRT represents a safe and viable treatment option in nodal oligometastatic setting. It provides excellent and durable local control with minimal toxicity. As distant progression remains the main challenge, careful selection in low-burden disease, dose escalation to BED10 ≥ 70 Gy, and thoughtful integration with systemic therapy emerge as key levers to optimize outcomes. Further prospective studies are needed to assess OMD long-term survival and quality of life and to evaluate possible further treatment optimization strategies.